408 - Safety and Immunogenicity of Meningococcal Serogroup B Vaccine (4CMenB) and 13-Valent Pneumococcal Vaccine (PCV13) Administered Concomitantly with Routine Infant Vaccines (RIVs) to Healthy United States (US) Infants: A Randomized Controlled Study

Presenting Author(s)

• DS

  Debasish Saha, MD, Phd

  Director
  GSK Vaccines
  Wavre, Brabant Wallon, Belgium

  Slides

Co-Author(s)

• LT

  Laura Tomasi Cont, PhD

  GSK
  Siena, Toscana, Italy
• WR

  Walter J. Rok, MD

  Pediatric Associates of Fall River
  Fall River, Massachusetts, United States
• 

  Judith M. Martin, MD (she/her/hers)

  Professor of Pediatrics
  University of Pittsburgh
  Pittsburgh, PA, United States
• PK

  Pavitra Keshavan, n/a

  GSK
  Siena, Toscana, Italy
• DM

  Danielle Morelle, n/a

  GSK
  Rixensart, Brabant Wallon, Belgium
• MT

  Mauro Trapani, PharmaD

  GSK
  Siena, Toscana, Italy
• EC

  Elisa Cinconze, n/a

  GSK
  Siena, Toscana, Italy
• ML

  Maria Lattanzi, MD, PhD

  GSK
  Siena, Toscana, Italy
• DT

  Daniela Toneatto, MD

  GSK
  Sienna, Toscana, Italy